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Axel Haverich, MD
Dr Haverich
Dear Hans,Now that it has been six years since you left your office (and theoperating room) at the medical school here in Hannover and asyou approach your 75th birthday, we know you have becomemore selective in your reading of medical articles. But I wouldlike to draw your attention to one article, for various reasons.
First, this article addresses the (hitherto thought) never-ending controversy about
medical versus surgical therapy for acute type B aortic dissections, a question in
which you were always extremely interested. Second, it (again) originates from the
Stanford group, whose members have been philosophically determined to answer
this question for some decades. Third, a (even for surgeons easily understandable)
statistical tool called “propensity score analysis” is now used to “upgrade” a
retrospective analysis into a prospective study, something you always dreamed of
during your active career. Finally, you will be surprised to know that the ultimate
answer to the question how to treat aortic type B dissections has been found.
However, new technology renders the question partly outdated (of course), posing
new questions to keep the gray substance of the next generation of surgeon
philosophers active. As both your former resident and current successor, I would
desperately like to hear your opinion regarding the paper of Craig Miller’s group.1
During the first months of my training, you taught me the differences between
acute versus chronic and type A versus type B aortic dissections. You always
preferred the Stanford classification system for two reasons: (1) its indicative value
for the type of surgical approach; (2) its inherent prognostic information. Our policy
then and for the next 20 years was the one exercised by most surgical groups,
including Stanford: medical treatment for uncomplicated acute type B dissections
and surgery for all type A dissections. Rupture and shock, malperfusion of distal
organs including paraplegia, and uncontrollable pain were the only indications for
surgery in distal dissections. This policy was disseminated to all residents, the
medical public in Germany, and, of course, our cardiology partners. When asked to
justify this approach, we quoted numbers associated with operative risk compared
with medical treatment, focusing on blood pressure control alone: 25% early
mortality after surgery compared with 16% with pharmacologic therapy.2 The
decision to avoid surgery for this indication, however, was also based on tremen-
dous technical difficulties. Problems related to proximal clamping, distal anastomo-
ses, and bleeding control after prolonged pump runs disqualified this operation to
probably the least attractive one next to limb amputation during my residency.
Ongoing malperfusion, paraplegia, and incomplete replacement of the diseased
aorta were some of the early and late complications amplifying our aversion to the
operation. In light of an operative mortality rate of 57% in the early experience of
the Stanford series, did we really want to see surgical outcome equalling or topping
that of medical treatment at that time? We have to keep in mind that deep
hypothermic circulatory arrest, a clinical tool revived by Griepp and coworkers3 in
1975, was not routine then, and even experienced radiologists were not able to
perform catheter-based interventions for malperfusion.
In this context, I find it remarkable that the Stanford group could reduce their
operative mortality from 57% 30 years ago to less than 10% over the past 10 years.
Of course, many groups may not be able to achieve this degree of excellence, even
taking into account that, in this article, only patients without malperfusion were
included in the surgical treatment group. This selective measure certainly has
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contributed to obtaining better results in this series than in
other centers. Furthermore, the introduction of cardiopul-
monary bypass and a more aggressive use of profound
hypothermic circulatory arrest4 in the past decade may
explain in part the significant improvements in outcome.
Catheter-based interventions for malperfusion have been
available in most institutions since the early 1990s. This
important adjunct most probably has influenced outcome in
both surgically and medically treated patients. Unlike those
in the Stanford group, patients with acute type B aortic
dissections who presented to other hospitals and who were
treated locally according to our recommendations were usu-
ally not admitted to our hospital. Therefore, such patients
were never included in our studies; the same probably holds
true for many other centers. Aortic dissections originating
beyond the origin of the left subclavian artery occur more
frequently in patients during their 6th or 7th decade of life.5
The high degree of age-related comorbidity in these patients
made our decision for medical treatment easier. For type A
dissections, the mean age usually ranges between 50 and 55
years.
The younger age as well as the dismal outcome of
patients with medically treated type A aortic dissections left
no doubt that urgent surgical therapy was indicated in these
cases. The outcome in the literature shows wide variations,
clearly depending on indications and techniques as well as
on experience and exposition.
For type B dissections, we believed that surgery should
indeed be advocated in some nonemergency cases. You,
Hans Georg, developed the elephant trunk technique to
facilitate distal aortic replacement after ascending and/or
aortic arch surgery.6 This idea was born from the dire
consequences associated with aortic repair in Marfan pa-
tients, who usually required more than one reoperation once
aortic dissection had occurred. Palma and associates7 in-
vented an elegant and at the same time aggressive and
defendant approach, further developing your technique. Via
median sternotomy, they introduced the elephant technique
(in normal arch anatomy) for patients with acute type B
aortic dissection. You were both proud and enthusiastic
after your visit to Brazil, and we were ready to introduce the
concept. Just as the Stanford group argues today, we be-
lieved then that we had patients in our cohort for whom
elective surgery was deemed appropriate. On the basis of
data regarding late reoperation in Marfan patients after
medical treatment,8 the Stanford group conclusively advo-
cates early intervention in these and other younger age
victims of acute type B dissection.
The method of endovascular stent grafting has been
shown to be an attractive alternative in patients with aneu-
rysms of the abdominal and thoracic aorta, especially those
with significant comorbidity. The value of this method for
dissecting aneurysms is still questionable because our ex-
perience is limited and long-term follow-up data are lack-
ing.
In Hannover, we introduced a surgical technique
whereby an aortic arch prosthesis is attached to a stented
graft for the descending aorta, placed through the open
aortic arch during hypothermic circulatory arrest and ante-
grade selective cerebral perfusion. This procedure can be
performed through a conventional median sternotomy and
combines the concepts of the elephant trunk principle and
endovascular stenting of descending aortic aneurysms or
dissections. Its advantage lies in the fact that the stented
graft, unlike a conventional elephant trunk prosthesis, can
be securely anchored at the desired level distal to the de-
scending aortic aneurysm, thereby allowing thrombus for-
mation within the space between the graft and the wall of
the aneurysm.9 Hans Georg, I think we both welcome the
idea per se of advocating early repair of the aorta, because
our own results both in aortic type A dissection and in type
B dissection clearly suggest the high risk of late reoperation
in these patients. Such an evaluation, however, has to be
stratified according to the underlying disease. Looking at
the total series at Stanford, the incidence of reoperation was,
in general, not higher in medically treated patients. Future
investigations, therefore, have to identify patients at higher
risk of aneurysm expansion, for example, connective tissue
disorders compared with atherosclerotic aortic disease. Be-
cause catheter-based techniques of aortic repair are less
invasive, future investigations also have to define the role of
this concept in acute type B dissections. Previous reports
suggest stent-graft placement to be an alternative in chronic
type B dissections; however, data related to the acute stage
of the disease remain scarce.10 Our own experience from
1990 comprises 122 patients, of whom only 14 had acute
type B dissection. For many good reasons, therefore, stent-
graft placement does not appear to be the ultimate answer in
acute type B dissection at this point. High urgency cases
based on complications of the disorder have to be clearly
separated from elective cases. The role of surgery should
increase; better techniques may also provide better results. I
would fully concur with Craig Miller’s group in demanding
prospective randomized and, because of the low number of
patients seen in individual institutions, multicenter trials
comparing surgery and stenting. Hans Georg, would you
also agree with such a proposal?
If one looks at the statistical analysis used in this report,
the Holy Grail of medical statistics, prospective randomized
trials, have, however, clearly seen better days. The analysis
includes 39 patients in a similar pretreatment risk situation
compared with medically treated patients. The 39 patients
were operated on over 36 years. Surgical mortality de-
creased from 57% to 10% over the decades; the comparison
with 119 medically treated patients has been found to be
statistically sound. This secret has a name: propensity score
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analysis. Hans Georg, let me briefly explain this to you. You
simply perform a multivariate analysis defining risk factors
for the type of intervention, in this case surgical versus
medical treatment. In this study, shock was a strong denom-
inator for surgery. If you exclude patients with significant
predisposing factors for either one of the treatment options,
you are left with 2 segments (out of 5, named quintiles) of
the initial population that would have qualified for both
treatment modalities. In this study, the number of medically
treated patients is reduced from 158 to 112, the number of
surgically treated patients, from 72 to 39 by using propen-
sity score analysis, but the remaining patients being com-
pared are similar in terms of risk of dying. You then
compare the data as you would in a prospective randomized
trial. This is what I called “upgrade” in my introduction.
Of course, Eugene Blackstone11 has introduced this
mathematic method into statistical tools for cardiothoracic
surgery. The first two papers to which it was applied were
published in the January issue of this Journal, both on
ischemic mitral valve surgery. I was impressed by the power
of this statistical method. But, looking at the current grading
system for evidence-based medicine (grade 1 being “expert
opinion,” grade 2, “single-center study reports,” grade 3,
“multiple single-center reports,” and grade 4, “prospective
randomized multicenter trials,” where does this new method
find its place? And how does it actually differ from retro-
spective matched pair analyses? At present, for me as a
cardiothoracic surgeon with only a borderline background
in medical statistics, the value of the new method remains
unclear. Using tremendous computing facilities, it certainly
allows for censoring data sets in retrospectively analyzed
patient cohorts. This may be especially important in acute
type B dissections, where prospectively randomized multi-
center trials are extremely difficult to perform. In this case,
the method has been helpful to clearly show us that surgical
treatment of acute type B aortic dissection is definitely not
significantly different in outcome compared with medical
treatment. After publication of this important message, we
will now start operating on acute type B dissection in all
Marfan patients and candidates younger than 60 years. Once
prospective trials are organized using durable stent grafts
not associated with high endoleak rates, and not wandering
with time, and without structural failure at midterm, we
would embark on such trials. This is what a landmark paper
does to a surgeon. What do you think, Hans Georg?
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